glp-1 patent Ozempic's problem: how Novo Nordisk lost control of a blockbuster drug. 💉 Demand for weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite As Novo's patent expires, GLP-1

Those with G6PD deficiency, kidney or liver damage/dysfunction, very low platelet count, high blood pressure, and congestive heart failure (CHF) may not qualify

doi: 10.1111/j.1365-2265.2008.03348.x [DOI] [PubMed] [Google Scholar] 85

Because of that, there are inherent risks associated with purchasing them from unreputable sources

The endocrinologist I have spoken with regularly about this has mentioned that semaglutide is more muscle sparing than Mounjaro, which raises interesting points about how wide this market may be in terms of each modality perhaps retaining a market share for a very specific type of body composition requirement

Other mechanisms include type I IgE auto-antibodies directed at self-antigens, CD4-positive T cells directed at the high-affinity IgE receptor, immune cell activating IgE, and histamine-releasing factors able to bind to IgE